Testing a treatment to improve bone strength in children with osteogenesis imperfecta
Preclinical testing of early life anti-myostatin therapy for osteogenesis imperfecta
This study is looking at a new treatment that could help make bones stronger in kids with osteogenesis imperfecta (OI) by blocking a protein that stops muscle growth, starting from a young age to see if it can improve their bone health and overall well-being.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10840238 on NIH RePORTER |
What this research studies
This research investigates a new therapy aimed at enhancing bone strength in children with osteogenesis imperfecta (OI), a genetic disorder that leads to fragile bones and muscle weakness. The approach involves inhibiting myostatin, a protein that limits muscle growth, starting from early life to potentially improve bone density and overall health. By using animal models, the researchers aim to understand how early intervention can lead to better outcomes for children affected by this condition. The study builds on previous findings that suggest early myostatin inhibition can significantly enhance bone quality.
Who could benefit from this research
Good fit: Ideal candidates for this research are infants and young children diagnosed with osteogenesis imperfecta.
Not a fit: Patients with osteogenesis imperfecta who are older or have already undergone significant treatment may not benefit from this early life intervention.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves bone strength and reduces the risk of fractures in children with osteogenesis imperfecta.
How similar studies have performed: Previous studies have shown promising results with myostatin inhibition in animal models, indicating potential for success in this novel approach.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Phillips, Charlotte L — University of Missouri-Columbia
- Study coordinator: Phillips, Charlotte L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.